Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

4.52USD
17 Nov 2017
Change (% chg)

$-0.11 (-2.38%)
Prev Close
$4.63
Open
$4.61
Day's High
$4.70
Day's Low
$4.43
Volume
240,403
Avg. Vol
353,718
52-wk High
$9.25
52-wk Low
$3.95

Select another date:

Thu, Nov 9 2017

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million‍​

* Files for mixed shelf of up to $200 million - SEC filing‍​ Source text: (http://bit.ly/2m4wZHE) Further company coverage:

BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication

* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication

BRIEF-Biocryst Pharmaceuticals prices public offering of common stock

* Biocryst Pharmaceuticals prices public offering of common stock

BRIEF-BioCryst Pharmaceuticals announces underwritten public offering​

* BioCryst Pharmaceuticals Inc - ‍offering to sell $80 million of its common stock in an underwritten public offering​

BRIEF-Biocryst announces positive results from mid-stage HAE trial

* Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE

BRIEF-Biocryst Pharmaceuticals Q2 loss per share $0.21

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Deerfield Management Co reports 6.81 pct passive stake in Biocryst Pharmaceuticals

* Deerfield Management Company, L.p reports a 6.81 percent passive stake in Biocryst Pharmaceuticals Inc as of may 25- sec filing Source text for Eikon: Further company coverage:

BRIEF-Biocryst announces Rapivab pediatric SNDA acceptance

* Says snda has a pdufa goal date for a decision by end of september 2017 Source text for Eikon: Further company coverage:

BRIEF-Robert Ingram named chairman of Biocryst Pharmaceuticals

* Robert Ingram named chairman of Biocryst Pharmaceuticals Inc

Select another date: